# **HDB Financial Services**



## Journey from an imperfect present to a better future

BFSI - NBFCs >

Result Update >

October 16, 2025

CMP (Rs): 743 | TP (Rs): 850

HDBFS posted an overall weak Q2FY26, with AUM growth (13% YoY), asset quality (GS3 +25bps QoQ to 2.81%), and credit cost (2.7%) coming in worse than consensus' and our estimates. The management pinned the reason of the poor show in Q2 to the CV/CE segments that saw increased stress due to heavy monsoon-led excessive idle time of vehicles (35% vs 20%). MSME The overall segment saw stabilization. Per the management's assessment, growth and asset quality bottomed out in Q2; H2 should see (already started) an improvement, supported by good monsoons and festive-season demand, and credit costs should normalize downward. Margins in the quarter improved by ~20bps QoQ mainly on account of CoF moderation. Beyond the H2 recovery, the mgmt remains confident of its ability to deliver steady growth (~18-20% CAGR over 3-5 years) with contained credit costs (~2.2%) ahead. Factoring in the Q2FY26 developments and management commentary, we marginally trim FY26E/28E AUM growth by ~1%/2.5%, and slightly increase our credit cost estimate by ~20bps which results in an EPS cut of 6-8% over FY26-28E. We maintain BUY on the stock while revising down Sep-26E target price by ~6% to Rs850 (Rs900 earlier), implying FY27E P/B of 2.8x.

#### CV/CE segment problems drive an all-around weak show

HDBFS reported a softer quarter in terms of AUM growth, credit cost, and asset quality, while NIM and opex were sequentially better. The muted disbursement and AUM growth are owing to continued stress in some segments (especially CV and CE), which are a major contributor to credit cost. Disbursement for the quarter stood at  $\sim$ Rs155bn (muted YoY;  $\sim$ 3% growth QoQ), resulting in AUM growing 2%/13% QoQ/YoY to Rs1.1trn. NIM expanded by  $\sim$ 20bps mainly on account CoF moderation. Credit cost for the quarter stood at  $\sim$ 2.7% (vs 2.5% in Q1FY26), largely due to stress in the CV/CE segments, while other asset classes were steady along with MSE and USL. Overall asset quality slightly declined, with GS3 inching up by  $\sim$ 25bps, while a healthy PCR of  $\sim$ 55%.

## With early signs of improvement, the mgmt remains hopeful of a better H2FY26

The mgmt indicated that it is seeing some early signs of credit demand growth across the segment (barring CV) in early-Q3FY26 and expects the trend to continue, along with recovery in the CV segment. The management expects H2 to see better growth, along with improvement in credit cost led by a good monsoon, strong festive demand, and overall macro improvement. It expects to deliver a steady growth of  $\sim$ 18-2% over the next 3-5 years with credit cost being contained at  $\sim$ 2.2%; it also indicated that the growth will be across products, with consumer finance growing at a faster pace.

#### Factoring in the Q2FY26 update, we maintain BUY while reducing TP to Rs850

Factoring in the Q2FY26 developments and management commentary, we marginally adjust FY26-28E EPS downward by 6-8% which results in a  $\sim$ 15-20bps cut in RoA. We reiterate BUY on the stock with a revised down Sep-26E TP by 5.6% to Rs850, implying FY27E P/B of 2.8x.

<b>HDB Financial Service</b>	ces: Finan	cial Snapsh	ot (Consoli	dated)	
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Net profits	24,608	21,760	25,774	33,817	41,755
AUM growth (%)	28.8	18.5	16.8	18.2	19.4
NII growth (%)	16.2	18.3	24.3	19.8	18.9
NIMs (%)	7.9	7.6	8.0	8.1	8.1
PPOP growth (%)	10.5	15.3	22.5	22.8	20.9
Adj. EPS (Rs)	31.0	27.3	31.1	40.8	50.3
Adj. EPS growth (%)	25.3	(11.9)	13.6	31.2	23.5
Adj. BV (INR)	173.3	198.8	251.9	292.7	343.0
Adj. BVPS growth (%)	19.9	14.7	26.7	16.2	17.2
RoA (%)	3.0	2.2	2.2	2.4	2.5
RoE (%)	19.5	This report	13.6	for Tools	hito Margue
P/E (x)	24.0	27.2	23.9	18.2	nite Marque 14.8
P/ABV (x)	4.3	3.7	3.0	2.5	2.2

Source: Company, Emkay Research

Target Price - 12M	Sep-26
Change in TP (%)	(5.6)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	14.4

Stock Data	HDBFS IN
52-week High (Rs)	892
52-week Low (Rs)	728
Shares outstanding (mn)	829.6
Market-cap (Rs bn)	617
Market-cap (USD mn)	7,002
Net-debt, FY26E (Rs mn)	NA
ADTV-3M (mn shares)	0
ADTV-3M (Rs mn)	1,344.2
ADTV-3M (USD mn)	15.3
Free float (%)	0.0
Nifty-50	25,323.6
INR/USD	88.1
Shareholding,	
Promoters (%)	0.0
FPIs/MFs (%)	0.0/0.0

Price Performance										
(%)	1M	3M	12M							
Absolute	(5.6)	(11.6)	0.0							
Rel. to Nifty	(6.5)	(12.1)	0.0							

## 1-Year share price trend (Rs)



# **Avinash Singh** avinash.singh@emkayglobal.com

+91-22-66121327

#### Kishan Rungta

kishan.rungta@emkayglobal.com

e Solutions (team.enkay@whitemarquesolution

Mahek Shah

mahek.shah@emkayglobal.com +91-22-66121218

**Exhibit 1: Actual vs Estimates** 

HDBFS - Q2FY26 result update											
(Rs mn)	Q2 FY25	Q3 FY25	Q4 FY25	Q1FY26	Q2FY26	YoY	QoQ	Q2FY26E	Variation	Conse	nsus
Business Assets	986,240	1,020,970	1,068,780	1,093,420	1,114,090	13.0%	1.9%	1,126,223	-1.1%		
Disbursement	156,850	162,730	176,430	151,710	155,990	-0.5%	2.8%	154744.2	0.8%		
NII	18,325	18,721	19,728	20,918	21,925	19.6%	4.8%	21,706	1.0%		
Total Income	24,083	24,988	26,156	27,257	28,514	18.4%	4.6%	28,460	0.2%		
PPoP	12,301	12,765	13,381	14,022	15,305	24.4%	9.1%	14,662	4.4%	14,543	5.2%
Provisions	4,310	6,357	6,338	6,697	7,483	73.6%	11.7%	6,724	11.3%		
PBT	7,991	6,408	7,043	7,325	7,822	-2.1%	6.8%	7,938	-1.5%		
PAT	5,910	4,723	5,310	5,677	5,814	-1.6%	2.4%	5,898	-1.4%	6,009	-3.2%
NIMs+ Fees	9.9%	10.0%	10.0%	10.1%	10.3%	42bps	25bps	10%	8bps		
Credit cost	1.77%	2.53%	2.43%	2.48%	2.71%	94bps	23bps	2.42%	29bps		
GS3	2.10%	2.26%	2.25%	2.56%	2.81%	71bps	25bps	2.50%	31bps		
NS3	0.84%	0.90%	0.99%	1.11%	1.27%	44bps	16bps	1.12%	16bps		

Source: Company, Emkay Research

**Exhibit 2: Change in estimates** 

Y/e Mar (Rs mn)		FY26E			FY27E			FY28E	
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
AUM	1,257,144	1,248,331	-0.7%	1,500,686	1,475,128	-1.7%	1,808,122	1,760,776	-2.6%
Disbursement	760,236	760,236	0.0%	897,079	881,874	-1.7%	1,085,465	1,040,611	-4.1%
Net interest income	92,869	92,515	-0.4%	112,246	110,848	-1.2%	134,722	131,755	-2.2%
Total Income	116,079	115,679	-0.3%	137,516	135,929	-1.2%	162,905	159,519	-2.1%
PPOP	62,082	61,728	-0.6%	77,088	75,812	-1.7%	94,138	91,633	-2.7%
Provisions	25,090	27,039	7.8%	27,811	30,298	8.9%	32,827	35,435	7.9%
PBT	36,992	34,689	-6.2%	49,277	45,514	-7.6%	61,312	56,198	-8.3%
PAT	27,485	25,774	-6.2%	36,613	33,817	-7.6%	45,554	41,755	-8.3%
EPS (Rs)	33.1	31.1	-6.2%	44.1	40.8	-7.6%	54.9	50.3	-8.3%
BVPS (Rs)	254	252	-0.8%	298	293	-1.8%	353	343	-2.8%
Networth	210,682	208,971	-0.81%	247,295	242,788	-1.82%	292,849	284,543	-2.84%
NIMs	7.99%	7.99%	0bps	8.14%	8.14%	0bps	8.14%	8.14%	0bps
NIM + Fees	9.98%	9.98%	0bps	9.97%	9.98%	1bps	9.85%	9.86%	1bps
Cost-to-Income	46.52%	46.64%	12bps	43.94%	44.23%	28bps	42.21%	42.56%	34bps
Adj. Cost-to-income ratio	41.82%	41.94%	11bps	40.24%	40.49%	26bps	39.35%	39.64%	30bps
Opex-to-AUM	4.64%	4.66%	1bps	4.38%	4.41%	3bps	4.16%	4.20%	4bps
Adj Opex-to-AUM	3.80%	3.81%	1bps	3.74%	3.77%	2bps	3.68%	3.70%	3bps
Loan book growth	17.62%	16.80%	-82bps	19.37%	18.17%	-120bps	20.49%	19.36%	-112bps
Disbursement growth	15.00%	15.00%	0bps	18.00%	16.00%	-200bps	21.00%	18.00%	-300bps
Credit costs	2.16%	2.33%	18bps	2.02%	2.22%	21bps	1.98%	2.19%	21bps
ROA	2.32%	2.18%	-14bps	2.61%	2.44%	-17bps	2.71%	2.54%	-17bps
ROE	14.4%	13.6%	-84bps	16.0%	15.0%	-102bps	16.9%	15.8%	-103bps

Source: Company, Emkay Research

## **Exhibit 3: Valuation matrix**

			F	P/BV (x)			P/E (x)			RoA (%)			RoE (%)		Book \	Value (Rs	/sh)		PS (Rs)	
	Price (Rs)	Upside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
At CMP	743	14%	2.9	2.5	2.1	21.4	16.4	13.3	2.4	2.6	2.7	15.0	16.3	17.0	255.5	301.0	356.9	34.7	45.4	55.9
AT TP	850		3.3	2.8	2.4	24.5	18.7	15.2												

Source: Company, Emkay Research


Exhibit 4	4: Quarterly	earnings /	snapshot
-----------	--------------	------------	----------

Quarterly Earnings Summary	Q2 FY25	Q3 FY25	Q4 FY25	Q1FY26	Q2FY26	YoY	QoQ
Interest Income	34,310	35,169	36,233	38,315	38,865	13.3%	1.4%
Interest Expenses	15,985	16,448	16,505	17,397	16,940	6.0%	-2.6%
Net Interest Income	18,325	18,721	19,728	20,918	21,925	19.6%	4.8%
Other Income	5,758	6,267	6,428	6,339	6,589	14.4%	3.9%
Income	24,083	24,988	26,156	27,257	28,514	18.4%	4.6%
Operating Expenses	11,782	12,223	12,775	13,235	13,209	12.1%	-0.2%
Operating Profit	12,301	12,765	13,381	14,022	15,305	24.4%	9.1%
Provisions	4,310	6,357	6,338	6,697	7,483	73.6%	11.7%
Credit cost (on avg. Business Assets)	1.77%	2.53%	2.43%	2.48%	2.71%	94bps	23bps
PBT	7,991	6,408	7,043	7,325	7,822	-25.1%	6.8%
Tax	2,081	1,685	1,733	1,648	2,008	-3.5%	21.8%
Reported PAT	5,910	4,723	5,310	5,677	5,814	-1.6%	2.4%
Networth (approx)	148,794	153,242	158,197	186,988	193,382	30.0%	3.4%
AUM	986,240	1,020,970	1,068,780	1,093,420	1,114,090	13.0%	1.9%
Disbursements	156,850	162,730	176,430	151,710	155,990	-0.5%	2.8%
GS3	2.10%	2.26%	2.25%	2.56%	2.81%	71bps	25bps
NS3	0.84%	0.90%	0.99%	1.11%	1.27%	44bps	16bps
PCR	60.69%	60.02%	55.95%	56.70%	54.73%	-596bps	-197bps
ROA	2.40%	1.80%	2.00%	1.90%	1.93%	-47bps	3bps
ROE	16.20%	12.50%	13.60%	13.20%	12.23%	-397bps	-97bps

Source: Company, Emkay Research


## **Result in charts**

Exhibit 5: Softer AUM growth on account of stress in some segments




Source: Company, Emkay Research

Exhibit 6: Sequential improvement seen in the Enterprise business and Asset Finance segment




Source: Company, Emkay Research

Exhibit 7: CoF moderation on account of rate cut




Source: Company, Emkay Research

**Exhibit 8: Margin improvement led by moderating CoFs** 




Source: Company, Emkay Research

**Exhibit 9: Opex ratio stable** 




Source: Company, Emkay Research

**Exhibit 10: Core opex marginally improves** 




Source: Company, Emkay Research

**Exhibit 11: Credit cost remains elevated** 




Source: Company, Emkay Research

Exhibit 13: Asset quality impacted by elevated stress in some segments




Source: Company, Emkay Research

**Exhibit 12: PAT in line with expectations** 



Source: Company, Emkay Research


Exhibit 14: Profitability impacted by higher credit costs



Source: Company, Emkay Research


# **Story in charts**

Exhibit 15: AUM expected to grow ~18% over FY26-28E




Source: Company, Emkay Research

Exhibit 16: Some slowdown in the vehicle segment hits disbursement in the near term




Source: Company, Emkay Research

Exhibit 17: Stable yields and moderating cost of borrowing




Source: Company, Emkay Research

Exhibit 18: Core fee income to improve over FY26-28E




Source: Company, Emkay Research

Exhibit 19: Margin improvement led by moderating CoFs




Source: Company, Emkay Research

Exhibit 20: Opex to moderate as efficiency improves




Source: Company, Emkay Research

Exhibit 21: Credit cost to remain elevated in the near term, led by segmental stress




Source: Company, Emkay Research

**Exhibit 23: Broadly stable asset quality** 




Source: Company, Emkay Research

Exhibit 22: PAT growth of above 20% in FY27-28E



Source: Company, Emkay Research

Exhibit 24: Profitability to improve as near term stress in some segments eases



Source: Company, Emkay Research

# **Earnings call highlights**

- The company's customer base grew to 21mn in Q2FY26, up 4% sequentially, underscoring its expanding retail franchise. The loan book stood at Rs1.11tn, up 13% YoY and 2% QoQ, with a well-balanced portfolio mix 73% secured and 27% unsecured.
- In Enterprise Lending, growth remained measured as the company maintained caution on unsecured business loans, which had been deliberately slowed over the past few quarters. The management reiterated that this book would be scaled up gradually as asset quality stabilizes. The Loan Against Property (LAP) portfolio remained steady and low on credit cost, with an average ticket size of around Rs2.5mn and negligible exposure to the micro-LAP segment (sub Rs1mn loans). Meanwhile, the gold loan business continued its strong traction, growing 40% YoY and 10% QoQ, supported by regulatory clarity and favorable gold prices.
- In Asset Finance, the commercial vehicle (CV) portfolio was impacted by seasonally weak demand and heavy monsoons, particularly in the northern and eastern regions. Flood-like conditions led to extended vehicle idling roughly 35% versus the usual 20% and caused temporary stress in the segment. Demand was also deferred, due to the GST rate rationalization. However, the management expects a rebound in Q3, aided by festive activity, improving utilization, and government-led infrastructure push. The focus remains on smaller and used CVs (used CVs form 9% and new CVs 16%, of the book), while exposure to HCVs is being kept within limits.
- The Consumer Finance segment saw moderate growth during the quarter, as some demand was deferred in anticipation of GST cuts. However, early trends in October suggest that demand has revived strongly across consumer durables, two-wheelers, and auto loans. The management expects this momentum to sustain through Q3 and Q4, supported by a good monsoon and festive spending.
- Asset quality excluding CV and construction equipment segments was stable. Gross Stage 3 assets inched up, to 2.81% (from 2.56% in Q1FY26), largely driven by seasonal factors, while the provision coverage ratio stood at ~55%. MSME and LAP portfolios remained resilient. The management reiterated that overall credit cost, which stood at 2.7% in Q2, should begin moderating from Q3 and stabilize at ~2.2% over a 3-5-year horizon.
- Margins continued their positive trend, improving to 7.9% (vs 7.7% in Q1FY26) on the back of yield optimization and lower cost of funds. Funding remains well-diversified, with a positive ALM gap across all maturity buckets up to five years.
- On the cost front, operating efficiency improved further, with the cost-to-income declining to 40.7% (from 42.7% in Q1). The company aims to maintain this ratio in the ~41–42% range and keep cost-to-assets at 3.6-3.7%.
- The Relationship Personal Loan product is a pre-approved, cross-sell offering for existing customers and continues to scale up rapidly, having clocked CAGR of ~40% over the past four years. It now forms around 8% of the overall book, with most customers coming from the consumer finance base, although some overlap exists with CV and construction equipment borrowers as well.
- Looking ahead, the management expects the consumer finance segment to grow faster, with its share rising gradually over the next few years, supported by rising rural and semi-urban consumption. The CV portfolio should normalize as idling reduces and demand revives, while enterprise lending and gold loans are expected to deliver steady growth.
- Guidance and Outlook
  - Credit cost expected to normalize at ~2.2% over a 3-5-year horizon.
  - AUM CAGR to sustain at 18-20% in the medium term.
  - NIMs to remain within the 7.9-8% range.

This report Cost-to-income to stay at around 41.5-42%; cost-to-assets at 3.6-3.7%.marquesolution

Festive recovery and infra-driven CV demand should support a strong Q3 performance.

## **HDB Financial Services: Consolidated Financials and Valuations**

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Interest Income	111,567	138,358	163,935	193,366	229,749
Interest Expense	48,643	63,902	71,420	82,517	97,995
Net interest income	62,924	74,456	92,515	110,848	131,755
NII growth (%)	16.2	18.3	24.3	19.8	18.9
Non interest income	30,144	24,645	23,164	25,081	27,764
Total income	93,068	99,101	115,679	135,929	159,519
Operating expenses	49,347	48,692	53,951	60,117	67,886
PPOP	43,721	50,409	61,728	75,812	91,633
PPOP growth (%)	10.5	15.3	22.5	22.8	20.9
Provisions & contingencies	10,674	21,130	27,039	30,298	35,435
PBT	33,047	29,279	34,689	45,514	56,198
Extraordinary items	0	0	0	0	(
Tax expense	8,439	7,519	8,915	11,697	14,443
Minority interest	-	-	-	-	
Income from JV/Associates	-	-	-	-	
Reported PAT	24,608	21,760	25,774	33,817	41,75
PAT growth (%)	25.6	(11.6)	18.4	31.2	23.
Adjusted PAT	24,608	21,760	25,774	33,817	41,755
Diluted EPS (Rs)	31.0	27.3	31.1	40.8	50.3
Diluted EPS growth (%)	25.3	(11.9)	13.6	31.2	23.5
DPS (Rs)	0	0	0	0	C
Dividend payout (%)	0	0	0	0	(
Effective tax rate (%)	25.5	25.7	25.7	25.7	25.7
Net interest margins (%)	7.9	7.6	8.0	8.1	8.3
Cost-income ratio (%)	53.0	49.1	46.6	44.2	42.6
PAT/PPOP (%)	56.3	43.2	41.8	44.6	45.6
Shares outstanding (mn)	793.1	795.8	829.6	829.6	829.6

Shares outstanding (mn)	793.1	795.8	829.6	829.6	829.6						
Source: Company, Emkay Research	1										
Asset quality and other metrics											
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E						
Asset quality											
GNPL - Stage 3	17,118	24,137	31,208	33,928	40,498						
NNPL - Stage 3	5,680	10,631	14,044	15,268	18,224						
GNPL ratio - Stage 3 (%)	1.9	2.3	2.5	2.3	2.3						
NNPL ratio - Stage 3 (%)	0.6	1.0	1.1	1.0	1.0						
ECL coverage - Stage 3 (%)	66.8	56.0	55.0	55.0	55.0						
ECL coverage - 1 & 2 (%)	2.7	2.1	2.0	2.1	2.1						
Gross slippage - Stage 3	-	-	-	-	-						
Gross slippage ratio (%)	-	-	-	-	-						
Write-off ratio (%)	1.5	2.1	1.8	1.7	1.6						
Total credit costs (%)	1.3	2.1	2.3	2.2	2.2						
NNPA to networth (%)	4.1	6.7	6.7	6.3	6.4						
Capital adequacy											
Total CAR (%)	19.3	19.2	19.8	19.0	18.1						
Tier-1 (%)	14.1	14.7	15.9	15.7	15.4						
Miscellaneous											
Total income growth (%)	4.7	6.5	16.7	17.5	17.4						
Opex growth (%)	0.0	(1.3)	10.8	11.4	12.9						
PPOP margin (%)	5.5	5.1	5.3	5.6	5.7						
Credit costs-to-PPOP (%)	24.4	41.9	43.8	40.0	38.7						
Loan-to-Assets (%)	93.7	95.1	94.8	94.9	95.1						
Yield on loans (%)	13.9	14.0	14.2	14.2	14.2						

7.5

6.4

7.9

6.1

7.6

6.5

7.5

6.7

7.5

6.7

Source: Company, Emkay Research

Cost of funds (%)

Spread (%)

<b>Balance Sheet</b>					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	7,931	7,958	8,296	8,296	8,296
Reserves & surplus	129,496	150,239	200,675	234,492	276,248
Net worth	137,427	158,197	208,971	242,788	284,543
Borrowings	743,307	873,977	1,004,906	1,194,854	1,435,032
Other liabilities & prov.	44,831	54,459	58,674	64,485	70,812
Total liabilities & equity	925,565	1,086,633	1,272,551	1,502,127	1,790,388
Net loans	867,213	1,033,430	1,206,221	1,425,870	1,701,970
Investments	33,803	20,601	22,661	24,927	27,420
Cash, other balances	6,479	9,505	18,305	22,915	29,151
Interest earning assets	907,495	1,063,536	1,247,187	1,473,712	1,758,541
Fixed assets	4,890	7,028	8,082	9,295	10,689
Other assets	13,180	16,069	17,282	19,120	21,159
Total assets	925,565	1,086,633	1,272,551	1,502,127	1,790,388
BVPS (Rs)	173.3	198.8	251.9	292.7	343.0
Adj. BVPS (INR)	173.3	198.8	251.9	292.7	343.0
Gross loans	902,179	1,068,776	1,248,331	1,475,128	1,760,776
Total AUM	902,179	1,068,776	1,248,331	1,475,128	1,760,776
On balance sheet	902,179	1,068,776	1,248,331	1,475,128	1,760,776
Off balance sheet	0	0	0	0	0
Disbursements	608,993	661,075	760,236	881,874	1,040,611
Disbursements growth (%)	35.9	8.6	15.0	16.0	18.0
Loan growth (%)	30.6	19.2	16.7	18.2	19.4
AUM growth (%)	28.8	18.5	16.8	18.2	19.4
Borrowings growth (%)	35.5	17.6	15.0	18.9	20.1
Book value growth (%)	19.9	14.7	26.7	16.2	17.2

Source: Company, Emkay Research

Valuations and key Ratios								
Y/E March	FY24	FY25	FY26E	FY27E	FY28E			
P/E (x)	24.0	27.2	23.9	18.2	14.8			
P/B (x)	4.3	3.7	3.0	2.5	2.2			
P/ABV (x)	4.3	3.7	3.0	2.5	2.2			
P/PPOP (x)	0.0	0.0	0.0	0.0	0.0			
Dividend yield (%)	0	0	0	0	0			
Dupont-RoE split (%)								
NII/avg AUM	7.9	7.6	8.0	8.1	8.1			
Other income	3.8	2.5	2.0	1.8	1.7			
Securitization income	-	-	-	-	-			
Opex	6.2	4.9	4.7	4.4	4.2			
Employee expense	4.8	3.7	3.4	3.2	3.0			
PPOP	5.5	5.1	5.3	5.6	5.7			
Provisions	1.3	2.1	2.3	2.2	2.2			
Tax expense	1.1	0.8	0.8	0.9	0.9			
RoAUM (%)	3.1	2.2	2.2	2.5	2.6			
Leverage ratio (x)	6.4	6.7	6.3	6.0	6.1			
RoE (%)	19.5	14.7	13.6	15.0	15.8			
Quarterly data								
Rs mn, Y/E Mar	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26			
NII	18,325	18,721	19,728	20,918	21,925			
NIM (%)	7.5	7.5	7.5	7.6	7.7			
PPOP	12,301	12,765	13,381	14,022	15,305			
PAT	5,910	4,723	5,310	5,677	5,814			
EPS (Rs)	7.44	5.93	6.67	6.84	7.01			

Source: Company, Emkay Research

#### **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
06-Oct-25	746	900	Buy	Avinash Singh
16-Jul-25	815	900	Buy	Avinash Singh
02-Jul-25	841	900	Buy	Avinash Singh

Source: Company, Emkay Research

#### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 16, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

#### Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 16, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 16, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

	· J ·····
Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

#### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.